Volume 393, Number 10175
9 March 2019
WORLD REPORT A committee brought together Senators and drug company representatives to discuss why drug pricing in the USA is so high, but little progress was made, Susan Jaffe reports.
A much-publicized Trump Administration proposal allows — not requires — pharmaceutical companies to pass large rebates on to Medicare patients. Savings as much as 30 percent for seniors depend on companies’ voluntarily cutting prices but several top drug makers tell Senate committee they can’t promise to do so. [Continued here.]
(Visited 151 times, 1 visits today)